LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3500
-0.0050 (-1.41%)
At close: Aug 10, 2026
LSL Pharma Group Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
Cash & Equivalents | 0.77 | 0.55 | 0.3 | 0.01 | 0.01 | - |
Cash & Short-Term Investments | 0.77 | 0.55 | 0.3 | 0.01 | 0.01 | - |
Cash Growth | 334.46% | 85.14% | 3600.00% | 0% | - | - |
Accounts Receivable | 6.71 | 5.5 | 4.95 | 2.68 | 1.23 | - |
Other Receivables | - | - | - | - | - | 0.02 |
Total Trade Receivables | 6.71 | 5.5 | 4.95 | 2.68 | 1.23 | 0.02 |
Inventory | 17.31 | 12.35 | 9.22 | 4.11 | 2.96 | - |
Other Current Assets | 1.49 | 5.7 | 1.02 | 0.41 | 0.21 | - |
Total Current Assets | 26.27 | 24.1 | 15.48 | 7.2 | 4.4 | 0.02 |
Net Property, Plant & Equipment | 32.38 | 32.77 | 22.94 | 14.75 | 13.92 | - |
Other Intangible Assets | 18.67 | 17.47 | 13.27 | 8.93 | 8.98 | - |
Goodwill | 2.44 | 0.16 | 0.16 | - | - | - |
Other Long-Term Assets | 0.24 | 0.24 | 1.77 | 0.02 | 0.02 | - |
Total Assets | 80.01 | 74.74 | 53.61 | 30.9 | 27.31 | 0.02 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
Accounts Payable | 8.96 | 6.23 | 5.3 | 5.98 | 6.12 | 0.09 |
Short-Term Debt | 8.28 | 2.53 | 2.56 | 3.77 | 3.78 | 0.11 |
Current Portion of Long-Term Debt | 1.47 | 0.87 | 1.45 | 5.22 | 1.58 | - |
Current Portion of Leases | 1.03 | 0.69 | 0.45 | 0.12 | 0.14 | - |
Unearned Revenue | - | - | - | - | 0.01 | - |
Total Current Liabilities | 19.73 | 10.31 | 9.75 | 15.07 | 11.62 | 0.2 |
Long-Term Debt | 25.82 | 26.66 | 12.75 | 4.73 | 7.84 | - |
Long-Term Leases | 7.1 | 7.61 | 4.66 | 2.44 | 2.56 | - |
Other Long-Term Liabilities | 3.19 | 3.19 | 1.79 | - | - | - |
Total Long-Term Liabilities | 36.12 | 37.46 | 19.2 | 7.17 | 10.4 | - |
Total Liabilities | 55.84 | 47.77 | 28.72 | 22.25 | 22.02 | 0.2 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
Common Stock | 40.47 | 40.47 | 36.39 | 24.2 | 15.05 | 2.93 |
Additional Paid-in Capital | 4.25 | 4.24 | 3.42 | 2.69 | - | 0.45 |
Retained Earnings | -20.55 | -17.74 | -14.92 | -18.23 | -9.76 | -3.56 |
Shareholders' Equity | 24.17 | 26.97 | 24.89 | 8.66 | 5.29 | -0.19 |
Total Liabilities & Equity | 80.01 | 74.74 | 53.61 | 30.9 | 27.31 | 17.31 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jul '21 Jul 31, 2021 |
Total Debt | 43.69 | 38.35 | 21.87 | 16.27 | 15.9 | 0.11 |
Net Cash (Debt) | -42.93 | -37.8 | -21.57 | -16.26 | -15.89 | -0.11 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.23 | -0.32 | -0.20 | -0.20 | -0.24 | -0.01 |
Book Value | 24.17 | 26.97 | 24.89 | 8.66 | 5.29 | -0.19 |
Book Value Per Share | 0.13 | 0.23 | 0.24 | 0.11 | 0.08 | -0.01 |
Tangible Book Value | 3.06 | 9.34 | 11.46 | -0.28 | -3.69 | -0.19 |
Tangible Book Value Per Share | 0.02 | 0.08 | 0.11 | -0.00 | -0.05 | -0.01 |